Telenzepine inhibits electrically-stimulated, acetylcholine plus histamine-mediated acid secretion in the mouse isolated stomach by blockade of M1 muscarine receptors.
1. The muscarine receptor mediating electrically-stimulated acid secretion in the mouse isolated stomach was characterized using a variety of muscarine receptor antagonists confirming the M1 nature of the antagonist effect of telenzepine. 2. Field stimulation (7 V, 10 Hz, 0.5 ms) resulted in a plateau acid secretion over at least 90 min which was completely blocked by either 1 mumol/l TTX or H2 receptor antagonists (100 mumol/l cimetidine or 10 mumol/l lupitidine). Ranitidine, which is known to potently inhibit mucosal acetylcholine esterase, was ineffective. Compound 48/80 at 100 mumol/l, which depletes mucosal histamine stores, initially mimicked electrical stimulation but subsequently prevented it from inducing acid secretion. 3. 10 muscarine receptor antagonists with differing relative affinities for M1, M2 and M3 receptors were introduced at 1 mumol/l to inhibit electrically-stimulated acid secretion. The percentages inhibition were plotted against binding affinities of the antagonists at either M1, M2 or M3 binding sites. A statistically significant correlation between functional and binding data was detected only when based on M1 affinities. 4. It is concluded that field stimulation, which probably mimicks vagal drive, results in muscarinic M1 receptor activation on paracrine cells to release histamine. Histamine then stimulates parietal cells to secrete acid. Hence, according to the present and our previous data, telenzepine inhibits acid secretion under these conditions by blocking M1 receptors at least partially located on histamine-releasing paracrine cells.
Kromer
W
W
Department of Pharmacology Byk Gulden Pharmaceuticals, Konstanz, Federal Republic of Germany.
Baron
E
E
Boer
R
R
Eltze
M
M
D000109:Acetylcholine / Q000502:physiology*; D000470:Alkaloids / Q000378:metabolism / Q000494:pharmacology; D000818:Animals; D000897:Anti-Ulcer Agents / Q000378:metabolism / Q000494:pharmacology; D004558:Electric Stimulation; D005663:Furans; D005744:Gastric Acid / Q000378:metabolism*; D005753:Gastric Mucosa / Q000378:metabolism*; D006632:Histamine / Q000378:metabolism / Q000494:pharmacology / Q000502:physiology*; D051379:Mice; D018727:Muscarinic Antagonists; D009281:Naphthalenes; D010276:Parasympatholytics / Q000378:metabolism / Q000494:pharmacology*; D010880:Piperidines / Q000378:metabolism / Q000494:pharmacology; D010890:Pirenzepine / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D013270:Stomach / Q000187:drug effects* / Q000294:innervation / Q000502:physiology / Q000648:ultrastructure; D013841:Thiazepines / Q000378:metabolism / Q000494:pharmacology; D014630:Vagus Nerve / Q000502:physiology; D003189:p-Methoxy-N-methylphenethylamine / Q000494:pharmacology
D000470:Alkaloids; D000897:Anti-Ulcer Agents; D005663:Furans; D018727:Muscarinic Antagonists; D009281:Naphthalenes; D010276:Parasympatholytics; D010880:Piperidines; D013841:Thiazepines; C046338:telenzepine; C058297:4-fluorohexahydrosiladifenidol; D010890:Pirenzepine; D003189:p-Methoxy-N-methylphenethylamine; C029165:BTM 1042; C042375:4-diphenylacetoxy-1,1-dimethylpiperidinium; D006632:Histamine; C046773:hexahydrosiladifenidol; C048172:himbacine; D000109:Acetylcholine; C048593:otenzepad